http://orcid.org/0000-0002-1359-8828
References
- Bateman TJ, Reddy VG, Kakuni M, et al. (2014). Application of chimeric mice with humanized liver for study of human-specific drug metabolism. Drug Metab Dispos 42:1055–65.
- Bissig KD, Han W, Barzi M, et al. (2018). P450-humanized and human liver chimeric mouse models for studying xenobiotic metabolism and toxicity. Drug Metab Dispos 46:1734–44.
- Chiu SH, Huskey SW. (1998). Species differences in N-glucuronidation. Drug Metab Dispos 26:838–47.
- Ghosal A, Yuan Y, Hapangama N, et al. (2004). Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm Drug Dispos 25:243–52.
- Hasegawa M, Kawai K, Mitsui T, et al. (2011). The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405–10.
- Higashi E, Ando A, Iwano S, et al. (2014). Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig. Biopharm Drug Dispos 35:313–20.
- Higuchi Y, Kawai K, Kanaki T, et al. (2016). Functional polymer-dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes. Hepatol Res 46:1045–57.
- Kamimura H, Ito S. (2016). Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica 46:557–69.
- Kamimura H, Ito S, Nozawa K, et al. (2015). Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers. Drug Metab Dispos 43:309–16.
- Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–10.
- Kazmi F, Barbara JE, Yerino P, Parkinson A. (2015a). A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos 43:523–33.
- Kazmi F, Yerino P, Barbara JE, Parkinson A. (2015b). Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos 43:1294–302.
- Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59–98.
- Lu D, Dong D, Wu B. (2018). Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10. Expert Opin Drug Metab Toxicol 14:989–98.
- Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94.
- Morgan MM, Khan DA, Nathan RA. (2005). Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 39:2056–64.
- Ramanathan R, Alvarez N, Su AD, et al. (2005). Metabolism and excretion of loratadine in male and female mice, rats and monkeys. Xenobiotica 35:155–89.
- Ramanathan R, Reyderman L, Su AD, et al. (2007). Disposition of desloratadine in healthy volunteers. Xenobiotica 37:770–87.
- Sanoh S, Nozaki K, Murai H, et al. (2012). Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos 40:76–82.
- Scheer N, Wilson ID. (2016). A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discov Today 21:250–63.
- Suemizu H, Kawai K, Murayama N, et al. (2018). Chimeric mice with humanized liver as a model for testing organophosphate and carbamate pesticide exposure. Pest Manag Sci 74:1424–30.
- Tang-Wai DF, Kajiji S, DiCapua F, et al. (1995). Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34:32–9.
- Uehara S, Higuchi Y, Yoneda N, et al. (2019). Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanised livers. Xenobiotica 49:678–87.
- Utoh M, Suemizu H, Mitsui M, et al. (2016). Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica 46:1049–55.
- Wang EJ, Casciano CN, Clement RP, Johnson WW. (2001). Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 29:1080–3.
- Xu D, Wu M, Nishimura S, et al. (2015). Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity. J Pharmacol Exp Ther 352:274–80.
- Yamazaki H, Suemizu H, Shimizu M, et al. (2012). In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol 25:274–6.